Scarica l'app Stockscreener
85.68
4.46%
-4.00
Dopo l'orario di chiusura:
85.68
Precedente Chiudi:
$89.68
Aprire:
$87.58
Volume 24 ore:
1.13M
Relative Volume:
1.16
Capitalizzazione di mercato:
$6.85B
Reddito:
$58.89M
Utile/perdita netta:
$-240.88M
Rapporto P/E:
-27.64
EPS:
-3.1
Flusso di cassa netto:
$-239.96M
1 W Prestazione:
-9.14%
1M Prestazione:
+31.94%
6M Prestazione:
+82.45%
1 anno Prestazione:
+103.37%
Intervallo 1D:
$84.58
$90.33
Intervallo di 1 settimana:
$84.58
$93.82
Portata 52W:
$19.45
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Nome
Kymera Therapeutics Inc
Settore
Industria
Telefono
857-285-5314
Indirizzo
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Confronta KYMR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
85.68 | 7.17B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Ripresa | Guggenheim | Buy |
| 2025-10-24 | Reiterato | B. Riley Securities | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-30 | Ripresa | B. Riley Securities | Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-20 | Ripresa | Stifel | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-12-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-26 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Iniziato | Oppenheimer | Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Iniziato | Truist | Buy |
| 2023-05-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Iniziato | Raymond James | Mkt Perform |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-08-03 | Iniziato | Goldman | Buy |
| 2022-07-20 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | JP Morgan | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2021-09-30 | Iniziato | B. Riley Securities | Neutral |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-09-15 | Iniziato | BofA Securities | Neutral |
| 2020-09-15 | Iniziato | Cowen | Outperform |
| 2020-09-15 | Iniziato | Guggenheim | Buy |
| 2020-09-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
Kymera Therapeutics Insider Sold Shares Worth $21,699,044, According to a Recent SEC Filing - marketscreener.com
Kymera's eczema drug gets fast track designation in the United States - MSN
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. - Barron's
Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 678 Shares - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 6,101 Shares of Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 229,809 Shares - MarketBeat
Eventide Asset Management LLC Increases Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
BVF Inc. IL Boosts Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics director Booth sells $21.7 million in stock By Investing.com - Investing.com Canada
Kymera Therapeutics director Booth sells $21.7 million in stock - Investing.com
Kymera Therapeutics (NASDAQ:KYMR) Director Buys $172,499,918.00 in Stock - MarketBeat
Kymera Therapeutics Soars on Robust KT-621 Trial Results - timothysykes.com
Kymera jumps on early-stage data for eczema candidate KT-621 - MSN
Kymera's Eczema Drug Gets Fast Track Designation in the United States - Your Wyoming Link
Kymera Therapeutics announces $500M proposed public offering - MSN
Redmile Group LLC Trims Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Mizuho Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise ... - Enidnews.com
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Kymera Therapeutics (NASDAQ: KYMR) raises $692.3M in upsized equity offering - Stock Titan
Kymera Therapeutics (KYMR) Valuation After KT-621 Fast Track Win and Strong Phase 1b BroADen Trial Data - Yahoo Finance
Kymera gains Fast Track status for oral candidate KT-621 for eczema - Seeking Alpha
KYMR: Analyst Stephens & Co. Raises Price Target to $110 | KYMR Stock News - GuruFocus
Kymera Therapeutics Says KT-621 Receives FDA Fast Track Designation in Atopic Dermatitis - marketscreener.com
KYMR Stock Rating: Mizuho Raises Price Target to $120 | KYMR Sto - GuruFocus
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis - Investing News Network
Kymera Therapeutics (KYMR) Receives FDA Fast Track for KT-621 in Atopic Dermatitis - GuruFocus
FDA grants fast track designation for Kymera’s oral AD treatment By Investing.com - Investing.com Canada
HC Wainwright Has Positive Estimate for KYMR FY2029 Earnings - MarketBeat
Kymera Therapeutics Granted FDA Fast Track Designation for KT-621 in Atopic Dermatitis Treatment - Quiver Quantitative
Kymera (NASDAQ: KYMR) gets FDA Fast Track for KT-621; Phase 2b AD study ongoing - Stock Titan
Marshall Wace LLP Acquires 67,384 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera (KYMR) jumps to all-time high as eczema treatment results impress - MSN
Norges Bank Invests $1.81 Million in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics prices $602M public offering at $86.00 a share - MSN
Kymera Therapeutics Announces Major Stock Offering - TipRanks
Kymera Therapeutics stock soars 46%. Why investors are excited about its anti-inflammatory drug. - MSN
Kymera Therapeutics raises $602M following positive clinical trial results for lead drug - The Business Journals
Eight biopharmas tap markets for $3.24B in early holiday rally - BioWorld MedTech
JP Morgan Raises Kymera Therapeutics (KYMR) Price Target to $125 - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $125.00 at JPMorgan Chase & Co. - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up After Analyst Upgrade - MarketBeat
Kymera Therapeutics stock price target raised to $134 from $84 at H.C. Wainwright - Investing.com UK
Avoiding Lag: Real-Time Signals in (KYMR) Movement - news.stocktradersdaily.com
KYMR Expands Common Stock Offering to $602 Million - GuruFocus
JPMorgan Chase & Co. Buys 160,848 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Prices $602 Million Common Share Offering - marketscreener.com
Kymera Therapeutics prices $602 million public offering of common stock - Investing.com India
Kymera Therapeutics prices $602 million public offering of common stock By Investing.com - Investing.com Australia
Kymera Therapeutics Announces Pricing of $602 Million Public Offering of Common Stock - Quiver Quantitative
Kymera Therapeutics Inc Azioni (KYMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):